Reversible Cystoid Macular Edema Secondary to Fingolimod in a Renal Transplant Recipient

Renal transplant remains the treatment of choice for end-stage renal disease.¹ Unfortunately, long-term graft failure rates are unsatisfactory. One potential therapy is fingolimod (FTY720), a new immunomodulator that reduces lymphocyte recirculation from lymphoid tissue to blood and peripheral tissues.² We describe a renal transplant recipient in a phase IIIb clinical trial of fingolimod who developed cystoid macular edema (CME).